[{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AG013","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Mouth Rinse","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"TerraCoV2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"TerraCoV2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avid Bioservices","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Terra CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Adjuvance Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"A.G.P.\/Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Oragenics \/ A.G.P.\/Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ A.G.P.\/Alliance Global Partners"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"CoV-2 S-2P","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ NIH"},{"orgOrder":0,"company":"Oragenics","sponsor":"Biodextris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BDX100","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inspirevax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ Inspirevax","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Inspirevax"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ National Research Council of Canada"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Inspirevax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"BDX301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"CQDM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"NT-CoV2-1","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ CQDM","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics \/ CQDM"},{"orgOrder":0,"company":"Oragenics","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Oragenics"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ ThinkEquity"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Avance Clinical"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Dawson James Securities"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oragenics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Oragenics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
